MilliporeSigma, an NEC member, has been granted a patent for CRISPR-chrom gene editing technology.
The CRISPR-chrom technology accesses and edits genomic DNA by fusing chromatin modulating peptides to Cas9, a protein that edits genes. This technology makes MilliporeSigma the only provider with a patent to increase access to DNA using chromatin modulators. The company was first awarded a patent for CRISPR in February 2019, which made CRISPR more efficient and specific. MilliporeSigma has researched CRISPR technology for 16 years and pursues research that takes into account the ethical and legal concerns surrounding gene editing.
“This award marks our second U.S. CRISPR patent and our 23rd CRISPR-related patent worldwide, and as a leading innovator of CRISPR technology, we will continue to drive innovation and collaborate with scientists around the world to ensure they have the most advanced gene-editing options,” said Udit Batra, CEO of MilliporeSigma.
The Council congratulates MilliporeSigma on their groundbreaking innovation in gene editing technology. Read more in P&T Community.
Recently from the Blog
Commonwealth Care Alliance Donates to RI Nonprofits